FDMT

2.77

3.99% -0.115

Handel nachbörslich: 2.77

4 D Molecular Therapeutics Inc (FDMT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$2.885

Offen:

$2.82

24-Stunden-Volumen:

559.86K

Relative Volume:

0.70

Marktkapitalisierung:

$128.26M

Einnahmen:

$20.72M

Nettoeinkommen (Verlust:

$-100.84M

KGV:

-1.0414

EPS:

-2.66

Netto-Cashflow:

$-78.56M

1W Leistung:

-23.69%

1M Leistung:

-30.23%

6M Leistung:

-72.22%

1J Leistung:

-89.98%

1-Tages-Spanne:

$2.67

$2.8527

1-Wochen-Bereich:

$2.67

$3.53

52-Wochen-Spanne:

$2.67

$29.27

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Firmenname

4 D Molecular Therapeutics Inc

Sektor

Healthcare (1162)

Branche

Biotechnology (673)

Telefon

(510) 505-2680

Adresse

5858 HORTON STREET #455, EMERYVILLE

Mitarbeiter

227

Twitter

Nächster Verdiensttermin

2024-12-13

Neueste SEC-Einreichungen

FDMT's Discussions on Twitter

Vergleichen Sie FDMT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
FDMT 4 D Molecular Therapeutics Inc	2.77	128.26M	20.72M	-100.84M	-78.56M	-2.66
VRTX Vertex Pharmaceuticals Inc	474.62	121.88B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	573.45	62.69B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	555.11	33.86B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	235.74	30.51B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	238.51	25.69B	3.81B	-644.79M	-669.77M	-6.24

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-13	Herabstufung	BMO Capital Markets	Outperform → Market Perform
2024-11-21	Eingeleitet	Morgan Stanley	Underweight
2024-09-23	Herabstufung	Cantor Fitzgerald	Overweight → Neutral
2024-04-15	Eingeleitet	Barclays	Overweight
2024-02-07	Fortgesetzt	Goldman	Buy
2023-10-26	Eingeleitet	RBC Capital Mkts	Outperform
2023-10-24	Eingeleitet	Cantor Fitzgerald	Overweight
2023-10-18	Hochstufung	Leerink Partners	Market Perform → Outperform
2023-07-05	Eingeleitet	Chardan Capital Markets	Buy
2023-01-30	Eingeleitet	BMO Capital Markets	Outperform
2022-11-18	Eingeleitet	H.C. Wainwright	Buy
2022-11-15	Hochstufung	Goldman	Neutral → Buy
2022-08-12	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2022-06-22	Eingeleitet	Jefferies	Buy
2022-01-04	Eingeleitet	SVB Leerink	Outperform
2021-01-05	Eingeleitet	BofA Securities	Buy
2021-01-05	Eingeleitet	Evercore ISI	Outperform
2021-01-05	Eingeleitet	Goldman	Neutral

Alle ansehen

4 D Molecular Therapeutics Inc Aktie (FDMT) Neueste Nachrichten

Mar 31, 2025

4D Molecular Therapeutics stock hits 52-week low at $3.46 - Investing.com India

Mar 31, 2025

4D Molecular Therapeutics stock hits 52-week low at $3.46 By Investing.com - Investing.com South Africa

Mar 31, 2025

Mar 30, 2025

Charles Schwab Investment Management Inc. Sells 29,708 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 30, 2025

Mar 27, 2025

PNC Financial Services Group Inc. Raises Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 27, 2025

4DMT to Participate in Upcoming Investor Conferences - GlobeNewswire

Mar 27, 2025

Mar 24, 2025

Here Is How Powerful 4D Molecular Therapeutics Inc (NASDAQ: FDMT) Stock Is - Stocks Register

Mar 24, 2025

Connor Clark & Lunn Investment Management Ltd. Raises Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 24, 2025

Weiss Ratings Reiterates Sell (E+) Rating for 4D Molecular Therapeutics (NASDAQ:FDMT) - The AM Reporter

Mar 24, 2025

Mar 21, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Short Interest Down 15.1% in February - Defense World

Mar 21, 2025

Mar 20, 2025

Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) PT at $30.63 - Defense World

Mar 20, 2025

Mar 16, 2025

M&T Bank Corp Boosts Stock Holdings in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 16, 2025

Mar 13, 2025

Proficio Capital Partners LLC Has $111,000 Position in 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 13, 2025

Mar 12, 2025

4D Molecular Therapeutics’ SWOT analysis: gene therapy firm faces durability hurdles - Investing.com

Mar 12, 2025

Mar 11, 2025

Are CytomX Therapeutics Inc (CTMX) shares a good deal now? - US Post News

Mar 11, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Price Target Cut to $40.00 by Analysts at Bank of America - Defense World

Mar 11, 2025

Mar 10, 2025

4DMT enrolls first patient in late-stage trial for its retinal eye disease therapy -March 10, 2025 at 09:31 am EDT - Marketscreener.com

Mar 10, 2025

4D Molecular announces first patients enrolled in 4FRONT-1 Phase 3 trial - TipRanks

Mar 10, 2025

4D Molecular Therapeutics Enrolls First Patients in Phase 3 Clinical Trial for 4D-150, Targeting Wet Age-Related Macular Degeneration - Nasdaq

Mar 10, 2025

4DMT Announces First Patients Enrolled in 4FRONT-1 Phase 3 Clinical Trial Evaluating 4D-150 in Wet AMD - GlobeNewswire

Mar 10, 2025

4D Molecular Launches Pivotal Phase 3 Trial for Revolutionary Eye Treatment - StockTitan

Mar 10, 2025

Mar 09, 2025

Rhumbline Advisers Acquires 3,675 Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) - Defense World

Mar 09, 2025

Mar 08, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given “Sell (D-)” Rating at Weiss Ratings - Defense World

Mar 08, 2025

Mar 07, 2025

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Shares Sold by New York State Common Retirement Fund - Defense World

Mar 07, 2025

FY2025 EPS Estimates for FDMT Boosted by Cantor Fitzgerald - Defense World

Mar 07, 2025

Analysts Issue Forecasts for FDMT Q1 Earnings - Defense World

Mar 07, 2025

Mar 05, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $28.00 Price Target at Chardan Capital - Defense World

Mar 05, 2025

Mar 04, 2025

2025 Market Prospects of Adeno-Associated Virus Vectors in Gene Therapy Pipeline: 200 Pipeline Drugs and the Strategic Workings of 180+ Companies - GlobeNewswire Inc.

Mar 04, 2025

Deeper Dive: Understanding 4D Molecular Therapeutics Inc (FDMT) Through its Various Ratios - The Dwinnex

Mar 04, 2025

4D Molecular price target lowered to $35 from $39 at RBC Capital - Yahoo Finance

Mar 04, 2025

Chardan Trims Price Target on 4D Molecular Therapeutics to $28 From $30, Keeps Buy Rating - Marketscreener.com

Mar 04, 2025

4D Molecular Therapeutics’ (FDMT) “Buy” Rating Reaffirmed at HC Wainwright - Defense World

Mar 04, 2025

Moderna (NASDAQ:MRNA) and 4D Molecular Therapeutics (NASDAQ:FDMT) Head to Head Review - Defense World

Mar 04, 2025

4D Molecular Therapeutics (NASDAQ:FDMT) Given New $35.00 Price Target at Royal Bank of Canada - Defense World

Mar 04, 2025

Mar 03, 2025

4D Molecular price target lowered to $28 from $30 at Chardan - TipRanks

Mar 03, 2025

Forecasting The Future: 7 Analyst Projections For 4D Molecular Therapeutics - Benzinga

Mar 03, 2025

RBC Lowers Price Target on 4D Molecular Therapeutics to $35 From $39, Keeps Outperform, Speculative Risk - Marketscreener.com

Mar 03, 2025

Mar 02, 2025

4D Molecular Therapeutics Full Year 2024 Earnings: Misses Expectations - Yahoo Finance UK

Mar 02, 2025

Mar 01, 2025

4D Molecular Therapeutics Reports Strong Clinical Progress and Financial Position - TipRanks

Mar 01, 2025

FDMT stock touches 52-week low at $4.4 amid sharp annual decline - Investing.com Australia

Mar 01, 2025

Feb 28, 2025

4D Molecular Therapeutics Inc reports results for the quarter ended September 30Earnings Summary - TradingView

Feb 28, 2025

4D Molecular Therapeutics, Inc. SEC 10-K Report - TradingView

Feb 28, 2025

4DMT Reports Full Year 2024 Financial Results, Operational Highlights and Expected Upcoming Milestones - The Manila Times

Feb 28, 2025

4D Molecular Therapeutics Reports Positive Clinical Data for 4D-150 in Wet AMD and DME, Outlines Strategic Pipeline and Financial Position - Nasdaq

Feb 28, 2025

Can 4DMT's $505M Cash Runway and Promising Eye Disease Data Overcome Rising Losses? - StockTitan

Feb 28, 2025

Feb 27, 2025

Spotlight On February 2025's Promising Penny Stocks - Simply Wall St

Feb 27, 2025

4D Molecular Therapeutics (FDMT) Projected to Post Earnings on Thursday - Defense World

Feb 27, 2025

Feb 25, 2025